logo-loader
viewCallitas Health Inc

Callitas Health succeeds with patent application for male fertility treatment

“Our ongoing work underscores our mission to helping couples with both female infertility and male infertility, for those trying to conceive,” said James Thompson, the interim president and CEO of Callitas

Couple in bed
Callitas's mission is to help couples trying to conceive

Callitas Health Inc (CNSX:LILY), a clinical-stage company focused on weight management and female health, has been granted a patent relating to fertility treatment.

The United States Patent and Trademark Office (USPTO) has granted notice of allowance for the company’s patent application for In Vivo Sperm Selection for Treating Male Infertility.

This patent notice of allowance expands Callitas's intellectual property portfolio and furthers the patent protected formula, and uses of, the ToConceive product, allowing it to be used to treat male infertility (or sub-fertility) caused by a reduced number of normal, functional sperm in the male partner.

“Male infertility (or sub-fertility) does not receive the attention it should,” said James Thompson, the interim president and chief executive officer of Callitas.

“Statistics indicate that nearly two-thirds of all infertility challenges are linked back to the male partner, and can be heightened with a lack of lubrication from the woman.

“This patent notice of allowance helps strengthen our core intellectual property assets of the ToConceive brand and reinforces Callitas’s commitment to female health and wellness,” Thompson added.

Callitas plans to expand its intellectual property portfolio with additional divisional applications from this current grant, as well as, additional patents in the female fertility and sexual wellness space.

Shares in Callitas were up 3.1% at C$0.33.

Quick facts: Callitas Health Inc

Price: - CAD

CSE:LILY
Market: CSE
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Callitas Health Inc named herein, including the promotion by the Company of Callitas Health Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Callitas Therapeutics signs LOI with Simply Wholeistic, updates on THC & CBD...

Callitas Therapeutics (CSE:LILY) (OTCQB:MPHMF) Vice President of Sales & Business Development Joshua Maurice tells Proactive Investors the pharma company has signed a letter of intent with Simply Wholeistic to manufacture  its CannaStrip products in the U.S. Maurice added that as...

on 04/25/2019

2 min read